Intranasal drug developer Impel NeuroPharma has announced the appointment of former Nivalis Therapeutics leader Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Congleton was most recently President and CEO of Nivalis and had previously served in a number of executive roles at Teva. He succeeds an interim CEO, co-Founder John Hoekman, who will continue as Executive VP and Chief Scientific Officer.
In December 2012, Impel announced that it had raised $36 million for development of intranasal CNS drugs. A few months later, the company said that it had entered into an agreement with Camargo Pharmaceutical Services for development services.
Congleton said, “Impel’s unique Precision Olfactory Delivery or POD nasal delivery platform addresses an underutilized route of administration for therapeutics and can represent a significant breakthrough in drug delivery of both small molecules and biologics. I am very excited to join the Impel team to help further develop the value of its deep pipeline to benefit CNS patients who are vastly underserved with current therapies.”
Impel Executive Board Chair Stewart Parker commented, “Impel has made impressive, ground-breaking scientific progress with its CNS pipeline and delivery platform. We are confident that Jon Congleton, with his impressive corporate leadership background and CNS product successes will now lead Impel’s transition from the lab to regulatory approval and commercialization of its assets.”
Read the Impel NeuroPharma press release.
